Clinical trial

ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

NCT06001255

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention HS-20093 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

ARTEMIS-003: HS-20093 in Patients With Metastatic Castrate-resistant Prostate Cancer (mCRPC) and Advanced Solid Tumors

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2024-01-18

PhasePHASE2

Conditions

Metastasis Castration Resistant Prostate Cancer(mCRPC)unresolved

Interventions

HS-20093DRUG

Sponsors & collaborators

Hansoh BioMedical R&D Companylead sponsor

Mapped research locations

WuhanChina2 ChangshaChina2 BeijingChina1 ShanghaiChina1 GuangzhouChina1 ChengduChina1 NanjingChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06001255 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.